Evidence map›Paper›PMID 37795436›Full record

ArticleFrontiers in oncology2023

Complete patient exposure during paediatric brain cancer treatment for photon and proton therapy techniques including imaging procedures.

Marijke De Saint-Hubert, Guillaume Boissonnat, Uwe Schneider, Christian Bäumer, Nico Verbeek, Johannes Esser, Jörg Wulff, Florian Stuckmann, Finja Suesselbeck, Racell Nabha and 9 more

Abstract read
In one paragraph

Article in Frontiers in oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Marijke De Saint-HubertBelgian Nuclear Research Center (SCK CEN), Mol, Belgium.
Guillaume BoissonnatCEA, Université Paris-Saclay, Palaiseau, France.
Uwe SchneiderPhysik Institut, Universitat Zürich, Zürich, Switzerland.
Christian BäumerWest German Proton Therapy Centre Essen WPE, Essen, Germany.
Nico VerbeekWest German Proton Therapy Centre Essen WPE, Essen, Germany.
Johannes EsserWest German Proton Therapy Centre Essen WPE, Essen, Germany.
Jörg WulffWest German Proton Therapy Centre Essen WPE, Essen, Germany.
Florian StuckmannWest German Proton Therapy Centre Essen WPE, Essen, Germany.
Finja SuesselbeckWest German Proton Therapy Centre Essen WPE, Essen, Germany.
Racell NabhaBelgian Nuclear Research Center (SCK CEN), Mol, Belgium.
Jérémie DabinBelgian Nuclear Research Center (SCK CEN), Mol, Belgium.
Fabiano VasiPhysik Institut, Universitat Zürich, Zürich, Switzerland.
Stephan RadonicPhysik Institut, Universitat Zürich, Zürich, Switzerland.
Miguel RodriguezHospital Paitilla, Panama City, Panama.
Anne Catherine SimonCEA, Université Paris-Saclay, Palaiseau, France.
Neige JournyINSERM U1018, Paris Sud-Paris Saclay University, Villejuif, France.
Beate TimmermannWest German Proton Therapy Centre Essen WPE, Essen, Germany.
Isabelle Thierry-ChefBarcelona Institute of Global Health (ISGlobal), Barcelona, Spain.
Lorenzo BruallaWest German Proton Therapy Centre Essen WPE, Essen, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: In radiotherapy, especially when treating children, minimising exposure of healthy tissue can prevent the development of adverse outcomes, including second cancers. In this study we propose a validated Monte Carlo framework to evaluate the complete patient exposure during paediatric brain cancer treatment. Materials and methods: Organ doses were calculated for treatment of a diffuse midline glioma (50.4 Gy with 1.8 Gy per fraction) on a 5-year-old anthropomorphic phantom with 3D-conformal radiotherapy, intensity modulated radiotherapy (IMRT), volumetric modulated arc therapy (VMAT) and intensity modulated pencil beam scanning (PBS) proton therapy. Doses from computed tomography (CT) for planning and on-board imaging for positioning (kV-cone beam CT and X-ray imaging) accounted for the estimate of the exposure of the patient including imaging therapeutic dose. For dose calculations we used validated Monte Carlo-based tools (PRIMO, TOPAS, PENELOPE), while lifetime attributable risk (LAR) was estimated from dose-response relationships for cancer induction, proposed by Schneider et al. Results: Out-of-field organ dose equivalent data of proton therapy are lower, with doses between 0.6 mSv (testes) and 120 mSv (thyroid), when compared to photon therapy revealing the highest out-of-field doses for IMRT ranging between 43 mSv (testes) and 575 mSv (thyroid). Dose delivered by CT ranged between 0.01 mSv (testes) and 72 mSv (scapula) while a single imaging positioning ranged between 2 Conclusion: The complete patient exposure during paediatric brain cancer treatment was estimated by combining the results from different Monte Carlo-based dosimetry tools, showing that proton therapy allows significant reduction of the out-of-field doses and secondary cancer risk in selected organs.

Indexed as

imaging dosimetryMonte Carlo simulationout-of-field dosimetryphoton radiotherapyproton therapysecondary cancer risk

Identifiers

PMID37795436
PMCPMC10546320

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.